<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03355170</url>
  </required_header>
  <id_info>
    <org_study_id>NEU-05.16</org_study_id>
    <nct_id>NCT03355170</nct_id>
  </id_info>
  <brief_title>Cardiac Safety of Lansoprazole and Domperidon Combination</brief_title>
  <official_title>Cardiac Safety Evaluation of Lansoprazole/Domperidone 30/30 mg Sustained Release Capsule Formulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Neutec Ar-Ge San ve Tic A.Ş</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Neutec Ar-Ge San ve Tic A.Ş</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of current study is to compare safety and efficacy of lansoprazole/domperidone 30/30
      mg sustained release capsules (brand name: Duolans) and lansoprazole 30 mg micropellet
      capsules (brand name: Lasotab) in GERD patients in terms of cardiac safety.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2018</start_date>
  <completion_date type="Anticipated">January 1, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in QT and corrected QT (QTc) interval compared to baseline</measure>
    <time_frame>8 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in upper gastrointestinal symptom severity index compared to baseline.</measure>
    <time_frame>8 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>GERD</condition>
  <condition>Cardiac Event</condition>
  <condition>Safety Issues</condition>
  <arm_group>
    <arm_group_label>Lansoprazole/Domperidone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient will be administered lansoprazole/domperidone 30/30 mg capsules (brand name: Duolans) half an hour before breakfast for eight weeks according to randomisation scheme.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Lansoprazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patient will be administered lansoprazole 30 mg capsules (brand name: Lasotab) half an hour before breakfast for eight weeks according to randomisation scheme.</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Lansoprazole/Domperidone</intervention_name>
    <description>Experimental</description>
    <arm_group_label>Lansoprazole/Domperidone</arm_group_label>
    <other_name>Duolans</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
    <description>Active comparator</description>
    <arm_group_label>Lansoprazole</arm_group_label>
    <other_name>Lasotab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  GERD patients with BMI 18-33 kg/m2

          -  Patients with esophagitis class A-B according to Los Angeles classification

        Exclusion Criteria:

          -  Patients whose long QT syndrome risk score &gt; 3.

          -  Patients with family history of short or long QT syndrome.

          -  Patients with Barrett's stricture, gastric outlet obstruction, malignancy,
             gastrointestinal system bleeding or any other upper gastrointestinal system pathology.

          -  Patients whose Hiatus hernia is &gt; 3 cm.

          -  Patients with uncontrolled or insulin dependent diabetes mellitus, symptomatic
             gallbladder stone, active or unhealed stomach or duodenum ulcer, Zollinger-Ellison
             syndrome, primary esophagus motility disorder, pancreatitis, inflammatory bowel
             disease, severe lung disease, chronic liver disease, uncontrolled kidney impairment,
             cancer (except skin cancer except melanoma), cerebrovascular disease, epilepsy.

          -  Patients with history of heart failure, ventricular tachycardia, ventricular
             fibrillation, cardiac arrest, Torsades de pointes, bradycardia, sinus node
             dysfunction, heart attack, long QTc (&gt;460 ms).

          -  Patients taken PPIs or H2-blockers within 7 days and prokinetic drugs within 3 days
             before entering the study.

          -  Patients with major psychiatric disease.

          -  Alcoholism and drug use.

          -  Patients with pathologic laboratory tests; hemogram, sedimentation, CRP, thyroid
             functions tests, liver enzymes.

          -  Malabsorption.

          -  Immunosuppressive patients.

          -  Patients taken cortisone.

          -  Patients taken other drugs that prolong QT interval.

          -  Patients taken drugs that need gastric acid for optimal absorption; ketoconazole, iron
             salts, digoxin, ampicillin esters, anticoagulants, antineoplastic agents,
             prostaglandin analogues, sucralfate, atazanavir, theophylline, tacrolimus,
             fluvoxamine, rifampisin, nefazodone and aprepitant.

          -  Patients taken drugs carried with P-glycoprotein, indicated for heart diseases,
             AIDS/HIV or infection treatment.

          -  Pregnancy or breast-feeding.

          -  Patients taken drugs that may affect gastrointestinal system motility or acid release.

          -  History of abdominal surgery (hysterectomy, abdominal hernia repair, caesarean cases
             may be included; cholecystectomy have to be excluded).

          -  Patients with hypocalcemia and hypercalcemia

          -  Patients taken NSAII drugs (paracetamol may be used up to 2 gr/day).

          -  Patients taken antidepressants.

          -  Hypersensitivity to study drugs.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Serhat Bor, Prof Dr</last_name>
    <role>Study Chair</role>
    <affiliation>Ege University Medical Faculty Gastroenterology Dep.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Neutec R&amp;D</last_name>
    <phone>00902128505102</phone>
    <phone_ext>0000</phone_ext>
    <email>iremkaraman@neutecrdc.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Başkent University Hospital Gastroenterology Dep.</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Birol Özer, Prof Dr</last_name>
      <email>birolozer@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Çukurova University Medical Faculty Cardiology Dep.</name>
      <address>
        <city>Adana</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mesut Demir, Prof Dr</last_name>
      <email>mdemir46@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ankara University Medical Faculty Gastroenterology Dep.</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mehmet Bektaş, Prof Dr</last_name>
      <email>Mehmet.Bektas@medicine.ankara.edu.tr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dışkapı Research and Training Hospital Gastroenterology Dep.</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elife Erarslan, Assoc Prof Dr</last_name>
      <email>elifeerarslan@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Yüksek İhtisas Research and Training Hospital Gastroenterology Dep.</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>İsmail Hakkı Kalkan, Assoc Prof Dr</last_name>
      <email>drismailster@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Antalya Research and Training Hospital Gastroenterology Dep.</name>
      <address>
        <city>Antalya</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ayhan Hilmi Çekin, Assoc Prof Dr</last_name>
      <email>ayhancekin@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Balıkesir University Medical Faculty Gastroenterology Dep.</name>
      <address>
        <city>Balıkesir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ayla Yıldız Savaş</last_name>
      <email>drmssa@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gaziantep Şahinbey Research and Training Hospital Gastroenterology Dep.</name>
      <address>
        <city>Gaziantep</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Abdullah Emre Yıldırım, Assoc Prof Dr</last_name>
      <email>draemreyildirim@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dr. Sadi Konuk Research and Training Hospital Gastroenterology Dep.</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aliye Soylu, Prof Dr</last_name>
      <email>aliyesoylu@superonline.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ümraniye Research and Training Hospital Gastroenterology Dep.</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Zuhal Çalışkan, Assoc Prof Dr</last_name>
      <email>caliskanzuhal@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ege University Medical Faculty Gastroenterology Dep.</name>
      <address>
        <city>İzmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Serhat Bor, Prof Dr</last_name>
      <email>serhatbor@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tepecik Research and Training Hospital Gastroenterology Dep.</name>
      <address>
        <city>İzmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Betül Paköz, MD</last_name>
      <email>betulpakoz@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Celal Bayar University Medical Faculty Gastroenterology Dep.</name>
      <address>
        <city>Manisa</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Elmas Kasap, Assoc Prof Dr</last_name>
      <email>elmaskasap@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sıtkı Koçman University Medical Faculty Gastroenterology Dep.</name>
      <address>
        <city>Muğla</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Burak Özşeker, Assoc Prof Dr</last_name>
      <email>burakozseker@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Recep Tayyip Erdoğan University Medical Faculty Gastroenterology Dep.</name>
      <address>
        <city>Rize</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Remzi Adnan Akdoğan, Assoc Prof Dr</last_name>
      <email>remziadnan@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cumhuriyet University Medical Faculty Gastroenterology Dep.</name>
      <address>
        <city>Sivas</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Özlem Yönem, Prof Dr</last_name>
      <email>ozlemyonem@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 20, 2017</study_first_submitted>
  <study_first_submitted_qc>November 27, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 28, 2017</study_first_posted>
  <last_update_submitted>December 12, 2017</last_update_submitted>
  <last_update_submitted_qc>December 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Domperidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

